Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16406945 | 1.00 | CTSK (0.33) | CTSKGRIK1GRIK2 | |
| SCHEMBL14243655 | 1.00 | CTSK (0.33) | CTSKGRIK1GRIK2 | |
| SCHEMBL16841347 | 0.85 | CTSK (0.32) | CTSKGRIK1GRIK2 | |
| SCHEMBL16088787 | 0.85 | GRIK1 (0.33) | GRIK1GRIK2 | |
| SCHEMBL16841348 | 0.85 | CTSK (0.32) | CTSKGRIK1GRIK2 | |
| SCHEMBL15587017 | 0.85 | GRIK1 (0.33) | GRIK1GRIK2 | |
| SCHEMBL9148069 | 0.85 | GRIK1 (0.33) | GRIK1GRIK2 | |
| SCHEMBL10755955 | 0.83 | — | — | |
| SCHEMBL13101791 | 0.83 | — | — | |
| SCHEMBL15587117 | 0.82 | GRIK1 (0.36) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-114957326-A | Synthesis method of beraprost sodium phosphine ylide intermediate | 吉尔多肽生物制药(大连市)有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-109196111-B | Process for producing optically active carboxylic acids, carboxylic acid salts and carboxylic acid derivatives containing triple bonds | 奇诺因药物和化学工厂私人有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11008594-B2 | Process for the preparation of triple-bond-containing optically active carboxylic acids, carboxylate salts and carboxylic acid derivatives | CHINOIN PHARMACEUTICAL AND CHEMICAL WORKS PRIVATE COMPANY LTD. (HU) | 2021-05-18 | — | — | US | disclosed |
| CN-107802623-B | Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders | 开曼化学股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| CN-106748951-B | Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions | 开曼化学股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-4487961-A | ANTIULCER, ANTIASTHMA, ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1984-12-11 | — | — | US | disclosed |
| US-4486598-A | ANTIULCER, ANTICOAGULANT, ANTIASTHMA | THE UPJOHN COMPANY (US) | 1984-12-04 | — | — | US | disclosed |
| US-4474802-A | 5,6,7-Trinor-4,8-inter-m-phenylene prostaglandin I2 derivatives useful in anti-ulcer, hypotensive and platelet aggregation inhibiting compositions | TORAY INDUSTRIES, INC. (JP) | 1984-10-02 | — | — | US | disclosed |
| EP-0092352-A1 | 9-Substituted carbacyclins | THE UPJOHN COMPANY (US) | 1983-10-26 | — | — | EP | disclosed |
| EP-0087237-A1 | Carbacyclin analogues | THE UPJOHN COMPANY (US) | 1983-08-31 | — | — | EP | disclosed |
| EP-0086611-A1 | 9-Substituted carbacyclin analogues | THE UPJOHN COMPANY (US) | 1983-08-24 | — | — | EP | disclosed |
| EP-0086612-A1 | 9-Substituted carbacyclin analogues | THE UPJOHN COMPANY (US) | 1983-08-24 | — | — | EP | disclosed |
| EP-0084856-A1 | 5,6,7-Trinor-4, 8-inter-m-phenylene prostaglandin I2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1983-08-03 | — | — | EP | disclosed |
| US-4359581-A | Process for the production of caracyclin intermediates | SCHERING AG (DE) | 1982-11-16 | — | — | US | disclosed |
| US-4191694-A | HYPOTENSIVE, ANTISECRETORY, ANTIULCER, ANTIARRHYTHMIA AGENTS; ANTICOAGULANTS, DIURETICS | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008594-B2 | Process for the preparation of triple-bond-containing optically active carboxylic acids, carboxylate salts and carboxylic acid derivatives | ACADM, CES1, ACE | CTSK 89/4885GRIK1 369/4885GRIK2 794/4885 |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | CTSK 3693/4885GRIK1 657/4885GRIK2 843/4885 |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | CTSK 3693/4885GRIK1 657/4885GRIK2 843/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | CTSK 3693/4885GRIK1 657/4885GRIK2 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.